HIV Aids Articles | Labiotech

Home HIV Page 3

Latest Posts

future cancer treatments adapted to hiv

Interview 12 Jun 2019

How Vaccines Could One Day Beat HIV

Vaccines are humanity’s biggest achievement against infectious diseases. But could they defeat HIV, a particularly crafty virus? José Luis Cabero, CEO of Spanish biotech AELIX Therapeutics shared his experience developing an HIV vaccine at Labiotech Refresh in Barcelona. The concept of a vaccine is simple — priming the immune system against a pathogen so that […]

June 12, 2019 - 5 minutesmins - By Jonathan Smith

CRISPR babies death risk

News and Trends 3 Jun 2019

‘CRISPR Babies’ Might Be at Risk of Dying Younger

Update (01/10/2019): The scientists behind the study have declared that the results were based on erroneous data, meaning the mutation they studied has a weaker effect on mortality than initially reported. A new study highlights the issues that can result from modifying human DNA without sufficient understanding of how it can impact our health. Last […]

June 3, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

GSK ViiV Healthcare Double HIV Treatment

News and Trends 4 Apr 2019

Update: Two-Drug HIV Treatment Effective for up to Three Years

Update (04/04/2019): ViiV Healthcare’s two-drug HIV treatment, Juluca, has successfully suppressed the HIV virus for up to three years in patients’ blood. In a clinical study, 513 HIV-infected people switched to daily pills of Juluca from their standard drug regimes, which included three or four different drugs. Juluca was effective at suppressing the virus for […]

April 4, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

HIV treatment monthly injection

News and Trends 11 Mar 2019

Monthly Injection Proves as Good as Daily Pills Against HIV in Phase III

Two phase III trials conducted by ViiV Healthcare have concluded that a monthly injection of two anti-HIV drugs is as effective as the standard daily treatment taken by people infected with HIV. The results showed that, after 11 months, the monthly treatment achieved virus suppression levels of over 90% and similar to those of conventional […]

March 11, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

HIV London blood cancer transplant

News and Trends 6 Mar 2019

Second Patient Achieves HIV Remission After Bone Marrow Transplant to Treat Cancer

For the second time in history, an HIV-positive patient with blood cancer has achieved HIV remission following a customized bone marrow transplant to treat their cancer from an HIV-resistant donor. The HIV-positive patient received a bone marrow transplant to treat the blood cancer Hodgkin’s lymphoma, from which he also suffered. The researchers used this cancer […]

March 6, 2019 - 3 minutesmins - By Jonathan Smith

HIV header small size

News and Trends 3 Jan 2019

Austrian Biopharma Reaches First HIV Vaccine Milestone

Hookipa Pharma has reached its first milestone in a partnership deal with US-based CAR T pioneers Gilead Sciences to develop an HIV vaccine using the Austrian company’s arenavirus-based technology. Hookipa’s lead candidate is a prophylactic vaccine for cytomegalovirus, a common infection that can be dangerous in people with weak immune systems, such as those with […]

January 3, 2019 - 2 minutesmins - By Helen Albert

ADVERTISEMENT

news roundup biotech crispr

Best in Biotech 31 Dec 2018

European Biotech’s Biggest News of 2018

With this year coming to a close, it’s now time to look back at the biggest biotech news stories of 2018 in Europe, which include CRISPR-Cas9 controversy, big financial deals, and spider silk airplanes. The year 2018 brought a lot of change to the biotech industry in Europe, with clinical trials, approvals and Brexit […]

December 31, 2018 - 12 minutesmins - By Jonathan Smith

HIV reservoir institut pasteur

News and Trends 21 Dec 2018

French Scientists Find a Weak Spot in HIV-Infected Cells

Researchers at the Institut Pasteur were able to selectively kill the cells where HIV hides from antiretroviral drugs, opening the way for a new form of HIV treatments. The reason why HIV comes back when a person stops taking antiretroviral therapy is that it remains hidden and undetected within immune T cells. In a study […]

December 21, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

HIV virus Zion

News and Trends 6 Nov 2018

Potential HIV Treatment Shows Early Stage Promise

According to Phase I/IIa trial results from an Israeli biotech, an HIV drug reduced patients’ HIV levels by up to 99%, and might one day become a new treatment for the infection. The trial, run by Zion Medical, found that the synthetic peptide drug reduced the level of viral RNA in patients’ blood by up to […]

November 6, 2018 - 3 minutesmins - By Jonathan Smith

ViiV hiv antiviral

News and Trends 31 Oct 2018

Forget Daily Pills: HIV Could Be Treated With Monthly Injections

A monthly antiviral injection may be as good as daily HIV drugs for suppressing infections, reports the British biotech ViiV Healthcare. This could make the treatment of HIV easier for patients and improve compliance. In the first five months of a Phase IIb trial, the company gave 274 HIV-infected adults three daily oral antiretrovirals. After […]

October 31, 2018 - 2 minutesmins - By Jonathan Smith

Aelix Therapeutics Gilead Functional HIV Cure

News and Trends 19 Oct 2018

Spanish Biotech Partners Gilead to Develop Functional HIV Cure

AELIX Therapeutics and Gilead will run a clinical trial testing a combination of treatments that has potential to let HIV-infected people ditch lifelong therapy. The trial, which will run in Spain, is planned to start in early 2019 and will recruit around 90 patients in the early stages of HIV infection. After receiving the […]

October 19, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

hiv cartoon Sur fi

News and Trends 15 Aug 2018

London Biotech Gets Positive Phase III Results for its Monthly HIV Treatment

ViiV Healthcare has shown its monthly two-drug HIV treatment works as well as a daily three-drug treatment, which could help reduce the total number of drugs taken by patients. In a Phase III trial that recruited 618 people, London biotech ViiV Healthcare aimed to see if adult HIV-positive patients who had been taking daily antiretroviral […]

August 15, 2018 - 2 minutesmins - By Alexander Burik

ADVERTISEMENT